AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39241318 — intervention group
Group type: COMPARATOR
Intervention: BBV152
Number of subjects: 50
Study 39241341 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (AG)
Number of subjects: 90
Study 39241341 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical massage (MG)
Number of subjects: 90
Study 39241341 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 90
Study 39241562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Short-Term Dynamic Psychotherapy (ISTDP)
Number of subjects: 37
Study 39241562 — intervention group
Group type: COMPARATOR
Intervention: Medical care as usual (MCAU) plus wait-list symptom monitoring (WL-SM)
Number of subjects: 37
Study 39241807 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture at 36.6°C
Number of subjects: 234
Study 39241807 — intervention group
Group type: COMPARATOR
Intervention: Culture at 37.1°C
Number of subjects: 234
Study 39241904 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel implant + oral levonorgestrel (LNG)
Number of subjects: 306
Study 39241904 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (IUD)
Number of subjects: 306
Study 39241904 — intervention group
Group type: EXPERIMENTAL
Intervention: 52 mg levonorgestrel IUD
Number of subjects: 306
Study 39241959 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-year arm of adjuvant imatinib
Number of subjects: 136
Study 39241959 — intervention group
Group type: COMPARATOR
Intervention: 3-year arm of adjuvant imatinib
Number of subjects: 136
Study 39241963 — intervention group
Group type: EXPERIMENTAL
Intervention: GC + EBV-CTL (four cycles of gemcitabine and carboplatin followed by six cycles of EBV-CTL)
Number of subjects: 330
Study 39241963 — intervention group
Group type: COMPARATOR
Intervention: GC (six cycles of gemcitabine and carboplatin)
Number of subjects: 330
Study 39241963 — intervention group
Group type: EXPERIMENTAL
Intervention: GC + EBV-CTL
Number of subjects: 330
Study 39242029 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-3D registration
Number of subjects: 10
Study 39242029 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-3D registration
Number of subjects: 10
Study 39242029 — intervention group
Group type: COMPARATOR
Intervention: 3D-3D registration and 2D-3D registration
Number of subjects: 10
Study 39242045 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component behavioral intervention to increase and maintain high fluid intake
Number of subjects: 1658
Study 39242045 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 1658
Study 39242045 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported stone events
Number of subjects: 1658
Study 39242054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (IL-2), dosage and duration not specified
Number of subjects: 0
Study 39242054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39242065 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week program of supervised aerobic training (AT)
Number of subjects: 80
Study 39242065 — intervention group
Group type: EXPERIMENTAL
Intervention: AT and low to moderate-intensity strength training
Number of subjects: 80
Study 39242065 — intervention group
Group type: EXPERIMENTAL
Intervention: AT and moderate to high-intensity strength training
Number of subjects: 80
Study 39242065 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based physical activity and exercise recommendations
Number of subjects: 80
Study 39242160 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided (pharmacogenetic (PGx)-CDS) group
Number of subjects: 300
Study 39242160 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SoC) group
Number of subjects: 300
Study 39242160 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided group (high-risk patients)
Number of subjects: 300
Study 39242160 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group (non-high-risk patients)
Number of subjects: 300
Study 39242164 — intervention group
Group type: EXPERIMENTAL
Intervention: App-delivered self-management support (selfBACK) as an add-on to usual care
Number of subjects: 297
Study 39242164 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 297
Study 39242171 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based deworming (SBD)
Number of subjects: 44574
Study 39242171 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based deworming (CBD)
Number of subjects: 44574
Study 39242247 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with focal boosts (60Gy in 20 fractions, boost dose up to 68Gy)
Number of subjects: 61
Study 39242247 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with focal boosts
Number of subjects: 61
Study 39242449 — intervention group
Group type: EXPERIMENTAL
Intervention: LVIS
Number of subjects: 231
Study 39242449 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterprise
Number of subjects: 231
Study 39242497 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day treatment with low-molecular weight heparin (dosage not specified)
Number of subjects: 100
Study 39242497 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of 5000 IU low-molecular weight heparin daily from surgery until discharge (approximately 10 days)
Number of subjects: 100
Study 39242497 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day treatment with low-molecular weight heparin
Number of subjects: 100
Study 39242497 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of 5000 IU low-molecular weight heparin
Number of subjects: 100
Study 39242499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine nasal spray (30 µg or 50 µg based on body weight)
Number of subjects: 159
Study 39242499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 39242499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine nasal spray
Number of subjects: 159
Study 39242508 — intervention group
Group type: EXPERIMENTAL
Intervention: Myosuit program (5 gait training sessions with Myosuit, followed by 6 weeks of home use)
Number of subjects: 34
Study 39242508 — intervention group
Group type: COMPARATOR
Intervention: Conventional program (4 gait training sessions, followed by 6 weeks of home period)
Number of subjects: 34
Study 39242877 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml crystalloid fluid bolus (FB)
Number of subjects: 130
Study 39242877 — intervention group
Group type: COMPARATOR
Intervention: Follow-up strategy (FU)
Number of subjects: 130
Study 39242999 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentorship relationships
Number of subjects: 543
Study 39242999 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender as a barrier
Number of subjects: 543
Study 39242999 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender as a barrier for mentors of other genders
Number of subjects: 543
Study 39242999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity as a barrier
Number of subjects: 543
Study 39242999 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers for white mentees
Number of subjects: 543
Study 39243012 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor Walk Group (OWG)
Number of subjects: 190
Study 39243012 — intervention group
Group type: COMPARATOR
Intervention: Workshop and 10 telephone reminders (WR)
Number of subjects: 190
Study 39243031 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment with unrestricted mask-access (34 different masks)
Number of subjects: 1484
Study 39243058 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation-based cognitive behavioral therapy (CBT)
Number of subjects: 0
Study 39243058 — intervention group
Group type: COMPARATOR
Intervention: General offender treatment program
Number of subjects: 0
Study 39243058 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 0
Study 39243075 — intervention group
Group type: EXPERIMENTAL
Intervention: Perennial malaria chemoprevention (PMC) using sulfadoxine-pyrimethamine (SP)
Number of subjects: 36
Study 39243075 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 36
Study 39243091 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care Group (KCG)
Number of subjects: 90
Study 39243091 — intervention group
Group type: EXPERIMENTAL
Intervention: White Music Group (WMG)
Number of subjects: 90
Study 39243091 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 90
Study 39243100 — intervention group
Group type: EXPERIMENTAL
Intervention: LightGBM model
Number of subjects: 6010
Study 39243100 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost model
Number of subjects: 6010
Study 39243100 — intervention group
Group type: EXPERIMENTAL
Intervention: SnapLogisticRegression model
Number of subjects: 6010
Study 39243100 — intervention group
Group type: EXPERIMENTAL
Intervention: SnapDecisionTree model
Number of subjects: 6010
Study 39243122 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation for atrial fibrillation (AF)
Number of subjects: 170017
Study 39243232 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest CPB tertile
Number of subjects: 578
Study 39243232 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcification presence
Number of subjects: 578
Study 39243232 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater calcium burden
Number of subjects: 578
Study 39243262 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR) using dedicated devices
Number of subjects: 279
Study 39243264 — intervention group
Group type: EXPERIMENTAL
Intervention: T-TEER with the TriClip implant
Number of subjects: 98
Study 39243268 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMPOON (laceration of the anterior mitral leaflet)
Number of subjects: 30
Study 39243268 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMPOON
Number of subjects: 30
Study 39243306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed field ablation (PFA)
Number of subjects: 32
Study 39243304 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib 80 mg once daily (q.d.)
Number of subjects: 353
Study 39243304 — intervention group
Group type: COMPARATOR
Intervention: Asciminib 40 mg twice daily (b.i.d.)
Number of subjects: 353
Study 39243304 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib 200 mg b.i.d.
Number of subjects: 353
Study 39243311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (35 mg twice daily, days -15 to -10) and decitabine (20 mg/m² daily, days -10 to -5) plus modified busulfan-cyclophosphamide (mBu/Cy) conditioning regimen
Number of subjects: 37
Study 39243386 — intervention group
Group type: EXPERIMENTAL
Intervention: SB16
Number of subjects: 457
Study 39243386 — intervention group
Group type: COMPARATOR
Intervention: DEN
Number of subjects: 457
Study 39243397 — intervention group
Group type: EXPERIMENTAL
Intervention: IO + IO
Number of subjects: 1362
Study 39243397 — intervention group
Group type: EXPERIMENTAL
Intervention: IO + TKI
Number of subjects: 1362
Study 39243397 — intervention group
Group type: COMPARATOR
Intervention: non-sRCC
Number of subjects: 1362
Study 39243418 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for LMBC
Number of subjects: 100
Study 39243794 — intervention group
Group type: EXPERIMENTAL
Intervention: VLA1553
Number of subjects: 754
Study 39243886 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose ExPEC10V (n=8)
Number of subjects: 24
Study 39243886 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ExPEC10V (n=8)
Number of subjects: 24
Study 39243886 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled ExPEC10V group (medium- and high-dose)
Number of subjects: 24
Study 39243886 — intervention group
Group type: EXPERIMENTAL
Intervention: ExPEC10V (medium- and high-doses)
Number of subjects: 24
Study 39243886 — intervention group
Group type: EXPERIMENTAL
Intervention: ExPEC10V medium-dose
Number of subjects: 24
Study 39243886 — intervention group
Group type: EXPERIMENTAL
Intervention: ExPEC10V high-dose
Number of subjects: 24
Study 39243886 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 24
Study 39243979 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-only (THO)
Number of subjects: 159
Study 39243979 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 159
Study 39244144 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway device (SGA)
Number of subjects: 1702
Study 39244144 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation (TI)
Number of subjects: 1702
Study 39244201 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BLa80 in maltodextrin (n=23)
Number of subjects: 46
Study 39244201 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=23)
Number of subjects: 46
Study 39244209 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib plus Bevacizumab first-line maintenance therapy
Number of subjects: 59
Study 39244480 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort scale
Number of subjects: 860
Study 39244480 — intervention group
Group type: COMPARATOR
Intervention: NRS (Numerical Rating Scale)
Number of subjects: 860
Study 39244490 — intervention group
Group type: EXPERIMENTAL
Intervention: SHJ002 ophthalmic solution (0.025%, 0.08%, and 0.25%)
Number of subjects: 12
Study 39244490 — intervention group
Group type: EXPERIMENTAL
Intervention: SHJ002 ophthalmic solution (0.25%)
Number of subjects: 12
Study 39244490 — intervention group
Group type: COMPARATOR
Intervention: Untreated eye (negative control)
Number of subjects: 12
Study 39244530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl inhalant (25μg/dose) administered via inhalation, up to six inhalations per episode with a minimum interval of 4 minutes between doses.
Number of subjects: 59
Study 39244530 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 59
Study 39244532 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + ablative therapy (SABR preferred)
Number of subjects: 180
Study 39244532 — intervention group
Group type: COMPARATOR
Intervention: SOC palliative-intent treatments
Number of subjects: 180
Study 39244554 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO program
Number of subjects: 4340
Study 39244595 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ (Tocilizumab) 8 mg/kg every 4 weeks to week 48
Number of subjects: 621
Study 39244595 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ to week 24 followed by BAT1806/BIIB800 to week 48
Number of subjects: 621
Study 39244595 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT1806/BIIB800 to week 48
Number of subjects: 621
Study 39244595 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 621
Study 39244627 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-102, irinotecan, and bevacizumab
Number of subjects: 35
Study 39244642 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous CD7 CAR-T cells
Number of subjects: 30
Study 39244736 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaf Expander®
Number of subjects: 150
Study 39244736 — intervention group
Group type: COMPARATOR
Intervention: RME
Number of subjects: 150
Study 39244893 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet treatment (DAPT)
Number of subjects: 678
Study 39245025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic and Static Fatigue Index for gross and pinch-grip fatigability
Number of subjects: 23
Study 39245025 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Fatigue Index for non-dominant side pinch grip
Number of subjects: 23
Study 39245025 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Fatigue Index for non-dominant side gross grip
Number of subjects: 23
Study 39245025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Fatigue Index for dominant side pinch grip
Number of subjects: 23
Study 39245031 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based CAB-LA PrEP care system
Number of subjects: 14
Study 39245053 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% aqueous povidone-iodine for skin preparation
Number of subjects: 5558
Study 39245053 — intervention group
Group type: COMPARATOR
Intervention: 2% alcoholic chlorhexidine for skin preparation
Number of subjects: 5558
Study 39245053 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 5558
Study 39245053 — intervention group
Group type: COMPARATOR
Intervention: Uncoated sutures
Number of subjects: 5558
Study 39245053 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency surgery
Number of subjects: 5558
Study 39245053 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 5558
Study 39245053 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA grade III-V
Number of subjects: 5558
Study 39245053 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of diabetes
Number of subjects: 5558
Study 39245053 — intervention group
Group type: EXPERIMENTAL
Intervention: Being an ex-smoker
Number of subjects: 5558
Study 39245053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer
Number of subjects: 5558
Study 39245053 — intervention group
Group type: EXPERIMENTAL
Intervention: Major surgery
Number of subjects: 5558
Study 39245055 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1011.1 (pentavalent; containing one additional A/H3N2 strain [Newcastle])
Number of subjects: 696
Study 39245055 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1011.2 (quadrivalent; B/Yamagata replaced with one additional A/H3N2 strain [Newcastle])
Number of subjects: 696
Study 39245055 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1012 (pentavalent; B/Yamagata replaced with two additional A/H3N2 strains [Newcastle and Hong Kong]) at 50.0 μg
Number of subjects: 696
Study 39245055 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1012 (pentavalent; B/Yamagata replaced with two additional A/H3N2 strains [Newcastle and Hong Kong]) at 62.5 μg
Number of subjects: 696
Study 39245055 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1010 (control group)
Number of subjects: 696
Study 39245055 — intervention group
Group type: EXPERIMENTAL
Intervention: Solicited adverse reactions
Number of subjects: 696
Study 39245055 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsolicited adverse events
Number of subjects: 696
Study 39245055 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety population
Number of subjects: 696
Study 39245060 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction radiotherapy (8 Gy) plus best supportive care
Number of subjects: 66
Study 39245060 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 66
Study 39245178 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz TMS
Number of subjects: 41
Study 39245178 — intervention group
Group type: COMPARATOR
Intervention: 10-Hz TMS
Number of subjects: 41
Study 39245182 — intervention group
Group type: EXPERIMENTAL
Intervention: Yolk-AKD
Number of subjects: 76
Study 39245182 — intervention group
Group type: EXPERIMENTAL
Intervention: White-AKD
Number of subjects: 76
Study 39245182 — intervention group
Group type: COMPARATOR
Intervention: BLC
Number of subjects: 76
Study 39245341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid combination of ProGlide (PP) and Angio-Seal (AS)
Number of subjects: 257
Study 39245341 — intervention group
Group type: COMPARATOR
Intervention: Dual ProGlide (PP)
Number of subjects: 257
Study 39245360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab (3 mg/kg intravenously every 2 weeks) for groups 1 and 2
Number of subjects: 193
Study 39245360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab (350 mg intravenously every 3 weeks) for groups 3 and 6
Number of subjects: 193
Study 39245360 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious treatment-emergent adverse events (grade ≥3) for groups 1-3
Number of subjects: 193
Study 39245360 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious treatment-emergent adverse events (grade ≥3) for group 6
Number of subjects: 193
Study 39245584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal Polysaccharide vaccine (PPSV23)
Number of subjects: 210
Study 39245584 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid Vi Polysaccharide vaccine (Typhim Vi)
Number of subjects: 210
Study 39245584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 39245679 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support (specifics not provided)
Number of subjects: 238
Study 39245687 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispectral optoacoustic tomography (MSOT)
Number of subjects: 10
Study 39245687 — intervention group
Group type: COMPARATOR
Intervention: Muscle magnetic resonance imaging (MRI)
Number of subjects: 10
Study 39245687 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 10
Study 39245687 — intervention group
Group type: COMPARATOR
Intervention: Spirometry
Number of subjects: 10
Study 39245687 — intervention group
Group type: COMPARATOR
Intervention: Muscle testing
Number of subjects: 10
Study 39245687 — intervention group
Group type: COMPARATOR
Intervention: Quality of life scores
Number of subjects: 10
Study 39245861 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ACoA collaterals
Number of subjects: 0
Study 39245861 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral circulation patency in unilateral ICA occlusion
Number of subjects: 0
Study 39245873 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTR-CM diagnosed using cardiac scintigraphy
Number of subjects: 315
Study 39245876 — intervention group
Group type: EXPERIMENTAL
Intervention: Line-field confocal optical coherence tomography (LC-OCT)
Number of subjects: 0
Study 39245876 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflectance confocal microscopy (RCM)
Number of subjects: 0
Study 39245876 — intervention group
Group type: COMPARATOR
Intervention: Both imaging techniques (RCM and LC-OCT)
Number of subjects: 0
Study 39245937 — intervention group
Group type: EXPERIMENTAL
Intervention: CABA-201 (fully human, 4-1BBz anti-CD19-CAR T cell therapy)
Number of subjects: 1
Study 39246594 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (specific type not detailed)
Number of subjects: 90
Study 39246594 — intervention group
Group type: COMPARATOR
Intervention: Control group - usual care
Number of subjects: 90